Vasospasm may cause accidental stenting, and diffuse vasospasm may also be seen after stenting. [1] [2] [3] [4] [5] Vasospasm during PCIs may cause bradycardia, hypotension, and slow flow, leading to the complaints of chest pain and discomfort.
Furthermore, vasospasm which develops during a procedure may increase procedural time and the amount of opaque agent, and may cause undesirable cardiac events as well. [6] [7] The most common method for patients who have developed vasospasm is the administration of nitroglycerine (NTG) through a catheter. Often, a sufficient outcome cannot be achieved because the dose is under 100 mcg. In most cases, doses are kept at 100 mcg or lower due to concern about hypotension. Hypotension may develop at higher doses of NTG. The use of a perforated balloon to deliver local NTG to a precise location at higher doses has not yet been studied. In our previous study, we demonstrated that the visualization of the distal of total occlusion with an iatrogenic perforated balloon is a safe, practical, and simple method. 8 In this study, we aimed to compare intracoronary NTG injection with the catheter administration of NTG to the spasm area with an external iatrogenically perforated balloon in patients who developed vasospasm during coronary angiography or coronary angioplasty.
2 | METHODS
| Patient selection
A total of 2896 patients who presented to our clinic with complaints of chest pain (acute coronary syndrome or diagnosed with high-risk stable angina pectoris with non-invasive tests), and who had undergone angiography between May 2016 and November 2017, were identified as the candidates for this study. Patients in cardiogenic shock, those with allergy to NTG or diffuse systemic disease (Behcet's disease, ankylosing spondylitis, vasculitis, hyperallergic response, or rheumatoid arthritis), those with a lesion in the saphenous graft, and those who declined participation were excluded.
A total of 1208 patients were excluded from the study, including 384 patients in whom the target lesion was localized in the left main coronary artery (LMCA) or the right coronary artery (RCA) in an angiography, and 824 patients with a coronary stenosis under 70%.
The remaining 1688 patients were consecutively randomized as 1/1 in two groups. The local NTG group included 844 patients, and the proximal NTG group 844 patients. These patients underwent percutaneous intervention. A total of 1512 patients who did not develop a new lesion were excluded from the study. The study was continued with patients who developed new lesions in the coronary area. This includes those with additional lesions developed after the decision for PCI and 0.014 guidewire was sent, and those for whom a new lesion developed during balloon stent application. Of these patients who develop new lesions, 91 patients were randomized in the proximal NTG and 85 patients in the local NTG groups. NTG was administered to these patients for newly developed lesions. In the proximal group, NTG was diluted with 10 cc isotonic NaCl solution infused through the catheter over 110 s. For the local group, 500 mcg NTG was delivered through a coronary balloon perforated externally from several points. Those with lesions that did not show any change with NTG application, and those that were well-circumscribed had opaque involvement inside, had cracks or prolapsed lumens, or showed filling defect in the lumen, were considered to have dissection or plaque shifts and excluded from the study. Ultimately, 70 patients in the proximal NTG group and 74 patients in the local NTG patients completed the study. All baseline characteristics of the patients were recorded ( Figure 1 : Flowchart of the study), ( Table 1 ).
The local ethics committee approved that the study complied with ethics principles, and the study was conducted following the Declaration of Helsinki.
| Definitions
Acute myocardial infarction was defined as at least one cardiac biomarker being higher than upper reference limit (URL) of the 99th Spasm was considered to be stenosis developing when a guidewire, stent, or balloon contacted the vascular endothelium during PCI procedure in patients who met the above-mentioned criteria and signed informed consent following standard angiography. 9 Stenosis was accepted as a dissected lesion and plaque rupture developing due to the procedure if it had an irregular sharp contour, if created double lines between the lumen and vessel wall, or if left an opaque residue. These lesions were stented and those patients were excluded from the study. A regularly contoured lesion was considered to be a spasm ( Figure 1 ).
| Standardization and definition of the complications and the side effects
Tachycardia: ≥%20 increase in heart rate.
Hypotension: ≥%20 decrease in systolic blood pressure. Major hematoma or major hemorrhage: Incidences of bleeding that required at least 1 unit blood transfusion, or causing more than 2 unit in Hb, leading to ≥20 mmHg increase in systolic blood pressure and ≥20%
in pulse in acute hemorrhage, were included in this parameter.
Angiographic Procedure: Among the patients with a palpable right or left radial artery, the radial regions of the patients determined eligible for the intervention with Barbeu and Allen tests were sterilized and covered with a sterile cover. Local anesthesia was then induced at the site with 0.02 prilocaine and mg nitroglycerin solution. Then, the radial artery was cannulated with 5F Glidesheath (Terumo® N.V. Leuven, Belgium). Next, 5000 IU unfractionated heparin and 12.5 mg diltiazem solution prepared in order to radial arterial occlusion and spasm were given as an intra-arterial bolus via the sheath.
After performing the right and left coronary angiography, a 0.014 hydrophilic PT2™ (Boston Scientific® Heredia/Costarica) moderate support guidewire was delivered to the coronary artery. The procedure was performed using a standard coronary (percutaneous transluminal coronary angioplasty) PTCA balloon, and Everolimus-eluting stent. A stenosis of regular contour and regular margins during the procedure which was initially not present was considered to be coronary spasm.
Proximal or local nitroglycerin was applied on these patients.
Proximal NTG procedure: This technique is a classical method applied in any laboratory. We standardized this method as follows. 500 mcg NTG diluted with isotonic NaCl solution to 10 cc was injected in 15 s directly to the coronary artery through a guiding catheter inserted to the ostium, and imaging was carried out after 10 s.
Perforation of the balloon and local NTG procedure: A 1.5 × 15 mm balloon was loaded on a 0.014 guidewire in the target vessel. The balloon was inflated to 10 atm outside the body with an inflation device. The balloon was perforated at 4-5 points with a blackened needle. Meanwhile, fluid was passed through the balloon in order to prevent air intake. The perforated balloon was advanced up to the spasm site via the guidewire (Figure 2 ).
When the balloon reached the spasm site, 500 mcg NTG diluted to 5 cc was injected from the posterior end of the balloon to this site over 15 s, and imaging was carried out after 10 s. Because fluid transit through the balloon was at a lower output, local NTG was diluted to 5 cc instead of 10 cc in order to equalize application durations with proximal NTG (Figure 3-6 ).
| Calculation method of the spasm solving success
Imaging was carried out using Siemens Artis Zee® (© Siemens Healthcare 2014 Germany) coronary angiography device. The diameters before the procedure (br), time of spasm (sr), and after NTG (fr) were measured using Quantitative Coronary Angiography program of the device. These measurements were entered to the formula that we have developed to standardize the evaluation. Owing the formula, spasm solving success (SSS) of the technique was calculated in % in each patient. Diameters before and after the procedure and success percentage in each patient were loaded to SPSS software. Success rates were compared between the two groups at 95% confidence interval using independent samples t-test (Table 2 and Figure 7 ).
| Definition of spasm solving success (SSS) formula
We developed this formula to determine quantitatively how much of the loss in vessel diameter which developed due to spasm was recovered with the treatment. For this purpose, we measured baseline diameter (br), diameter at time of spasm (sr), and diameter after NTG using QCA interface of the angiography device. Approximately 90% of the loss by spasm was recovered with NTG.
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| Statistical analysis
Continuous variables are expressed as mean ± standard deviation.
Continuous variables were analyzed at 95% (Confidence interval) CI
FIGURE 2
In vitro puncturing of the balloon. Passing isotonic solution through perforated balloon to prevent air embolism, and insertion of the balloon into the catheter while the fluid is still exiting the balloon with independent sample t-test and one-way ANOVA. P < 0.05 values were considered statistically significant. The changes in diameter before and after NTG were compared with independent sample t-test, and it was found that the treatment was efficient in both groups. Loss by spasm compared to the baseline diameter was similar between the two groups. Spasm solving success percentages of both groups were compared with independent sample t-test at 95%CI. Nominal variables were compared by Chi-square and Fisher's Exact-tests. P < 0.05 was considered to be statistically significant.
| RESULTS
The mean age of the patients was 63 ± 13 years, with 48% being female. Baseline characteristics of all patients were comparable in two groups, as shown in Table 1 . (Table 2 ). In addition, spasm solving success was significantly better in the local NTG group (91.66 ± 14.09% vs 75.99 ± 16.86%, P < 0.001).
| Comparison of the results
In these results, incidences of procedure related hypotension (10% vs 52%, P < 0.001) and tachycardia (20% vs 57%, P < 0.001) were significantly lower in the local NTG group.
In terms of complications that developed due to the procedure, no significant differences were observed between both groups. One patient in the local NTG group, was brought to the hospital 2 days after the procedure due to wide anterior myocardial infarction, and the ejection fraction of the patient was found to be 35% in the echocardiography performed after the procedure. The patient was lost after 3 days due to hypotensive shock. Another patient from the proximal group was brought to the hospital at the 5th h due to a large inferior and posterior myocardial infarction. This patient developed malignant arrhythmia 6 h after the procedure and was lost despite administration of a standard dose of amiodarone and CPR for 45 min.
Both patients presented to the hospital with subacute myocardial infarction, and died from the causes related to MI. No correlation was found between these deaths and the procedure (Table 2 ).
| DISCUSSION
In this study, we compared efficiency and safety of local NTG injection through a perforated balloon and proximal NTG injection through a The most commonly used pharmacological treatment is NTG injection through a catheter. Hypotension and tachycardia are not frequent at low doses of 50-100 mcg. Success rates increase at high doses; however, patients may feel sick and develop hypotensive attack at levels above 250 mcg. Impaired hemodynamics may complicate the procedure. [11] [12] [13] This is an undesirable situation for any cardiologist.
Local NTG injection to the spasm site using the perforated balloon technique causes much less hypotension and tachycardia despite increased dosages (500 mcg NTG in this study). Furthermore, this method is more effective than conventional proximal NTG administration.
Vasospastic angina may be seen due to endothelial dysfunction, decreased synthesis of nitric oxide, intimal hyperplasia, and unexplained | 771 genetic predisposition in some persons. In fact, these patients may be presenting for the first time with acute coronary syndrome. In addition, it is known that coronary spasm may occur during coronary interventions.
Sometimes this vasospasm may be extremely severe. Persistent coronary spasms developing during the procedure or manifesting with a stent and resulting in mortality have been reported in the literature. We believe that for such cases, local NTG injection in the relevant site at higher doses would be more efficient. 2, 7, 14, [15] [16] [17] [18] In a search of Medline and Google Scholar, four publications were found describing intracoronary drug delivery distally through a microcatheter. NTG was administered through a microcatheter in two of these reports, with verapamil and diltiazem in the other two reports. Both drugs were found to be efficient in addressing no reflow.
However, we found no publication on "local NTG" for an application addressing coronary spasm. [19] [20] [21] [22] In our previous publication about the first application, which we termed the "True Lumen Test" in which opaque agent was delivered to the distal through a perforated balloon in order to show the occluded coronary distal, we have described how the balloon was perforated and used for this purpose. In addition, we compared this application with Over the Wire (OTW) balloon, and demonstrated that this method is more advantageous and has less side effect profile and a lower cost compared to the OTW balloon application. 8 It is obvious that the immediate termination of significant coronary spasms is of paramount importance for the success of the procedure.
In this study, we have shown that local NTG injection with the perforated balloon method is more useful and safer than proximal NTG delivery to the coronary artery. The same procedure can also be performed with microcatheter or OTW balloon. However, we believe that local NTG application to the site of vasospasm with a perforated balloon is more advantageous than microcatheter or OTW balloon, and preferred the perforated balloon technique in this study (Table 2) .
It is necessary to withdraw 0.014 guidewire in order to deliver the drug through microcatheter or OTW balloon. The lumen may thus be lost when the wire is withdrawn. In the perforated balloon technique, it
is not necessary to withdraw 0.014 guidewire, and there is no loss of lumen. In addition, it is necessary to use long guidewire of 260 or 300 cm with microcatheter or OTW balloon methods. In addition, an eruption perpendicular to the vessel lumen cannot be achieved when injecting a drug with a microcatheter or OTW balloon. The fluid delivered exits from the main lumen of the catheter rapidly toward the distal and parallelly to the endothelium. Since this flow is not catheter is riskier than treatment using a perforated balloon.
In our method, the drug rapidly erupts perpendicular to the endothelium from the small holes in the balloon. Thus, the drug comes into more contact with the endothelium. The drug reaching direct contact with the endothelium better penetrates at higher concentrations, and is absorbed from the vessel walls at higher doses.
Furthermore, due to the reciprocation of the balloon, it is possible to focus the drug on the desired site and deliver higher doses with a lower side effect profile. This method can be used in any laboratory in a simple way to address spasms. No additional costs will be incurred.
| Study limitations
We were concerned that the evaluation was affected by our use of NTG at the sheath site and the use diltiazem in order to prevent radial arterial cannulation and radial artery spasm. However, equality appears not to have been disrupted in the comparison, because we used same amounts of diltiazem and local NTG to the radial region for all patients. Second, identification of coronary spasm using (intravascular ultrasound) IVUS would increase the value of the study. We could not use IVUS in this study, since this would increase costs. However, further studies using IVUS would be valuable. In addition, further larger multicenter singleblind studies would be beneficial in order to better evaluate effectiveness of the method and NTG.
| CONCLUSION
In this paper, we present a novel method in which local NTG is injected to the spasm site of coronary artery using a perforated balloon. This method is much more successful in addressing spasm compared to NTG delivered with a catheter. It is safer since it is not necessary to withdraw the 0.014 guidewire. Its outcomes are much better than proximal NTG in terms of side effects. Local NTG application creates more local effect and has fewer side effects compared to proximal NTG. This is likely due to greater absorption of NTG by the tissue in spasm site, delaying access to the venous system. Local NTG is more effective than proximal NGT in addressing spasms.
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